ASEP Medical Holdings Inc. focuses on acquiring research and development assets in life sciences and medical diagnostics. The company shows a strong gross margin of 118.5%, indicating potential in its offerings, but faces significant concerns with negative EBITDA and net margins of -480.6% and -650.2%, respectively. Additionally, a low current ratio of 0.32 suggests liquidity issues, while minimal debt (0.05 debt/equity) provides some financial stability. The high margins juxtaposed with poor profitability and low market cap raise questions about sustainable growth and operational efficiency.
Loading financial metrics...
Company is burning $226K per quarter with $511K in cash. Approximately 2.3 quarters of runway at current burn rate.
Company posted a loss of $-3.1M over the last year, representing 1043.1% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $906K over the last year.
Exceptional revenue growth of 1307.7% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 508.1 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 33085.0pp, demonstrating strong operational leverage.
Both gross margin (+508.1pp) and operating margin (+33085.0pp) are expanding simultaneously, indicating the company is scaling profitably.
Fortress balance sheet: cash covers total debt 2.2×, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (September 30, 2025)